Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Radiography of both knees with a posterior-anterior, fixed flexion view taken during the Screening period. The index knee must show evidence of chronic OA.~* Moderate to severe pain in the index knee associated with OA must be stable for a minimum of 2 months prior to Screening, as assessed by the Investigator.~* A specified mean pain score in the index knee over the 7 days prior to dosing, based on question A1 of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC A1).~* Specified baseline and screening scores on the WOMAC A1~* Body Mass Index ≤ 45 kg/m2.~* Subjects must have had a therapeutic failure (no relief, or inadequate relief), and/or AEs resulting in stopping treatment, and/or contraindication to the standard of care appropriate to the severity of the index knee OA pain they are experiencing.~Exclusion Criteria:~* Joint replacement surgery of the index knee at any time, or open surgery of the index knee in the past 12 months.~* Prior arthroscopic surgery of the index knee within 3 months of Screening.~* Any painful conditions of the index knee due to joint disease other than OA.~* Mild pain in the non-index knee when walking.~* Other chronic pain anywhere in the body that requires the use of analgesic medications.~* Secondary OA of the index knee due to acute traumatic injury.~* Significant current or past instability (e.g., cruciate ligament tear or rupture or previous repair) or misalignment (\> 10 degrees varus or valgus) of the index knee~* Has used topical capsaicin on the index knee within 90 days of Screening.~* Corticosteroid injection in the index knee within 90 days of Screening.~* Received IA viscosupplementation (e.g., Synvisc®, Hyalgan®) within 90 days of Screening.~* Prior participation in an ALGRX 4975 or CNTX-4975 study.~* Has any of the following characteristics:~  1. active or historic substance use disorder within the previous year as defined by the Diagnostic and Statistical Manual for Mental Health Disorders, fifth edition, or~ 2. tests positive upon urine drug screen for a substance of abuse.~* Has moderate to severe depression or anxiety.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive a single injection of placebo into the index knee following local anesthesia and adjunct joint cooling.
- 0.5 mg CNTX-4975 (Type: EXPERIMENTAL): Subjects will receive a single injection of 0.5 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
- 1.0 mg CNTX-4975 (Type: EXPERIMENTAL): Subjects will receive a single injection of 1.0 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.

Based on this trial design, predict the completion outcome and termination type (if applicable).